News
-
Novartis has announced FDA approval for the Seebri Neohaler glycopyrrolate DPI and the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD. According to the company, both inhalers should be available in the first quarter… Read more . . .
-
AstraZeneca Canada has announced the availability of the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI in Canada for the treatment of COPD. Health Canada issued a Notice of Compliance for Duaklir Genuair on April 2, 2015.… Read more . . .
-
Dr. Reddy’s Laboratories, Princeton, NJ We are seeking a highly talented senior level Analytical Chemist (Director Level) at Dr. Reddy’s in Princeton NJ. This position would be responsible for all analytical activities for the co-development… Read more . . .
-
GlaxoSmithKline has announced results from the 26-week AUSTRI postmarketing study comparing the safety of Advair Diskus fluticasone propionate/salmeterol DPI to fluticasone propionate monotherapy for the treatment of asthma. According to GSK, the study demonstrated that… Read more . . .
-
Glenmark Pharmaceuticals announced that it has obtained semi-exclusive rights develop and market a generic fluticasone/salmeterol DPI in 15 European countries as part of an agreement with Polish pharmaceutical company Celon Pharma. The countries covered in… Read more . . .
-
The business meeting of AAPS’s Inhalation and Nasal Technology Focus Group (INTFG), which will take place on October 27 during the 2015 AAPS Annual Meeting in Orlando, FL, will include a talk by Next Breath… Read more . . .
-
Meda Pharmaceuticals in Canada has announced that Health Canada has approved Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of moderate-to-severe seasonal allergic rhinitis for patients age 12 years old and older who do… Read more . . .
-
The FDA has issued a drug shortage report for Foradil Aerolizer formoterol fumarate inhalation powder due to discontinuation of the product. According to the FDA website: “Novartis (manufacturer) and Merck have jointly decided to voluntarily… Read more . . .
-
GlaxoSmithKline has announced data from two studies demonstrating that the Incruse Ellipta umeclidinium DPI produced statistically significant increase in FEV1 at 12 weeks in COPD patients compared to tiotropium and was non-inferior to glycopyrronium. GSK… Read more . . .
-
The 2015 Drug Delivery to the Lungs meeting promises a diverse program focused on some of the latest trends in inhaled drug development. At least 500 OINDP specialists are expected to attend DDL 26, December… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.